Where the final dosage form is a sterile aluminium hydroxide-adjuvanted aqueous suspension for intramuscular delivery in breeding swine, the Erysipelothrix rhusiopathiae antigen concentrate is received as a titre-normalised liquid, typically after batch fermentation of a serovar-positive production strain, chemical inactivation, and tangential-flow concentration. The formulation step must reconcile the API’s phosphate-buffered salt background with the adjuvant’s surface charge, because phosphate ions present at 0.01 M can replace surface hydroxyl groups on aluminium oxyhydroxide and reduce antigen binding. The inactivated antigen concentrate is therefore diafiltered against 20 mM Tris-HCl at pH 7.2–7.4 before blending, and the adjuvant is added as a pre-equilibrated aluminium hydroxide gel to a final aluminium concentration of 1.5 mg/mL. The addition ratio is titre-normalised rather than fixed by volume; for a lot released at 2.0 × 10^10 CFU/mL pre-inactivation and a target final antigen load of 5.0 × 10^8 CFU/mL, the required concentrate addition is 2.5% v/v of final bulk before adjuvant adsorption. Final bulk is preserved with 0.01% w/v thiomersal in multi-dose containers, filled through a 5 µm in-line filter under ISO Class 7 background and ISO Class 5 unidirectional airflow according to ISO 13408-1. Batch release includes sterility by Ph. Eur. 2.6.1, identity by slide agglutination against homologous antiserum, and potency by challenge in mice relative to a reference bacterin under USDA 9 CFR 113.67. Terminal product is a 2 mL intramuscular injection given to gilts at 6–7 weeks before breeding and re-vaccinated at 4–6 week intervals; shelf-storage is 2–8°C, and freeze-thaw excursions are incompatible because adjuvant flocculation creates an unreadable opacity and uneven dose delivery.

Why Does Lyophilised Live Antigen Require a Residual Moisture Specification Below 2.0%?

For live attenuated vaccine powders prepared for reconstitution and subcutaneous injection, the terminal processing step is lyophilisation rather than sterile liquid filling. The Erysipelothrix rhusiopathiae API is harvested in late logarithmic phase at a cell density of 1 × 10^9–5 × 10^9 CFU/mL, then clarified and mixed with a stabiliser system before freeze-drying. Published data for this specific configuration is limited; the formulation matrix is product-specific, but commonly applied stabilisers include sucrose at 5% w/v, gelatin at 1.5% w/v, and monosodium glutamate at 0.5% w/v in a phosphate-free buffer. The addition ratio is batch-titre dependent because the fill target is defined by final vial CFU count after reconstitution; if the concentrate is standardised to 4.0 × 10^10 CFU/mL and the fill target is 2.0 × 10^8 CFU per 10-dose vial, then 0.05 mL of concentrate is added per vial before stabiliser topping, a ratio that is recalculated for every bulk antigen lot. The freeze-drying cycle uses a shelf pre-freeze at −45°C, primary drying at a product temperature near −25°C with chamber pressure at 80 µbar, and secondary drying at 25°C until residual moisture is verified below 2.0% by Karl Fischer titration. Moisture above 2.0% is associated with accelerated loss of viable count during long-term storage at 2–8°C; the API manufacturer therefore specifies both moisture and final oxygen headspace as release parameters. The terminal product is a lyophilised plug in a 10-dose or 50-dose glass vial, reconstituted with sterile water for injection within 4 hours of use. Identity, purity, and avirulence are assessed according to the applicable live erysipelas vaccine requirements in USDA 9 CFR; sterility is not applicable to live cultures, but extraneous-agent testing is mandatory before release.

When Parvovirus and Leptospira Antigens Co-Occupy the Aluminium Hydroxide Adsorbent

Combined vaccines for pre-breeding sow programs place chemically distinct antigen classes on the same aluminium hydroxide surface, creating a binding-capacity risk that must be resolved before filling. The Erysipelothrix rhusiopathiae component is introduced as an inactivated cellular antigen, while the parvovirus component is a non-enveloped viral antigen and the Leptospira component is a proteinaceous outer-envelope antigen; each competes for hydroxyl groups and phosphate exchange sites on the adjuvant crystal surface. The formulation is therefore designed as a sequential adsorption process: Leptospira antigens are adsorbed first at pH 7.0 at 25°C, followed by the erysipelas component at pH 7.4, and then the parvovirus fraction under low-shear mixing at 100 rpm. Addition ratios are expressed in relative potency units rather than volume percent; the erysipelas concentrate is added to achieve 1.0 relative potency per dose in the mouse challenge assay referenced in USDA 9 CFR 113.67, while the exact volumetric addition is derived from the API lot’s pre-inactivation titre. Free-antigen leakage is monitored by particle-free centrifugation and ELISA; a free-antigen fraction above 10% of total added antigen triggers reformulation. The downstream filling line must handle a suspension with a density near 1.05 g/cm³ and a viscosity below 10 cP at 25°C, using a reciprocating piston filler with piston ID optimised for 2 mL dose accuracy. The terminal product is a 2 mL intramuscular suspension administered to gilts and sows at pre-breeding and during gestation according to label timing. The complete batch release matrix must satisfy the relevant component monographs and ISO 13408-1 aseptic process requirements; published data for this specific erysipelas–parvovirus–leptospira configuration is limited at the named API level because the antigen source varies among manufacturers.

For autogenous bacterins manufactured from a farm-confirmed Erysipelothrix rhusiopathiae isolate, the API is supplied as a non-standardised cellular concentrate and is exempt from the full product-licensing pathway only within regional autogenous vaccine provisions. The isolate is expanded from liver or splenic swabs onto serum-enriched agar, then transferred to a stirred-tank fermentation at 37°C under reduced oxygen tension; published data for this specific configuration is limited, but autogenous bacterins commonly target a final inactivated cell concentration of 1 × 10^9 CFU/mL in the finished suspension. The addition ratio is therefore arrived at by cell-count measurement after concentration, not by a fixed volume; a 10% v/v final aluminium hydroxide gel is often used, though regional formulations may use water-in-oil adjuvants in ruminants. Inactivation is performed with formaldehyde at 0.3% w/v for 48 hours at 37°C, followed by neutralisation and sterility testing under Ph. Eur. 2.6.1. The downstream process is small-batch filling into 50 mL or 100 mL glass vials in a Class A cabinet; terminal product is a 1 mL subcutaneous injection for turkeys and sheep where the erysipelas serovar has been isolated and antimicrobial control is insufficient. Release is based on identity by slide agglutination, sterility, and safety in the target species; potency testing for autogenous products is often limited to target-species challenge in a subset of production lots.

Needle-Free Device Compatibility and the Injectable Suspension Viscosity Constraint

When the downstream administration route is a high-pressure needle-free injector rather than a hypodermic needle, the finished Erysipelothrix rhusiopathiae suspension must meet a particle-size and viscosity envelope that conventional needle formulations do not require. Published data for this specific configuration is limited; the device-facing constraints are nevertheless well characterised. The suspension is adjusted to a viscosity below 5 cP at 25°C and passed through a 75 µm stainless steel mesh before filling to remove aggregates that would block the nozzle or form local high-velocity jets. The formulation addition ratio is shifted toward lower adjuvant solids: aluminium hydroxide gel is reduced to 1.0% w/v rather than 2.0% w/v to maintain device backpressure, and the antigen concentrate addition is recalculated to preserve the same final antigen load per 0.5 mL intradermal dose. Filling for needle-free cartridges is performed at ambient temperature with nitrogen flushing; the terminal product is a 0.5 mL single-use cartridge or vial for intramuscular or intradermal administration in piglets and finishers. Process validation includes ISO 13485:2016 for the device assembly line and ISO 13408-1 for aseptic filling; the vaccine itself remains subject to the applicable veterinary medicinal product authorisation. Because needle-free injection generates a narrow tissue depot at higher pressure, the adjuvant distribution and antigen release profile are verified by target-species serology after administration; published data on Erysipelothrix rhusiopathiae-specific needle-free delivery is limited, and the adoption of this route depends on device-specific marketing-authorisation wording for the finished vaccine.